1. Home
  2. ANL vs SXC Comparison

ANL vs SXC Comparison

Compare ANL & SXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$10.20

Market Cap

731.6M

Sector

N/A

ML Signal

HOLD

Logo SunCoke Energy Inc.

SXC

SunCoke Energy Inc.

HOLD

Current Price

$9.42

Market Cap

764.5M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANL
SXC
Founded
2004
1960
Country
United States
United States
Employees
N/A
848
Industry
Steel/Iron Ore
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
731.6M
764.5M
IPO Year
2022
2011

Fundamental Metrics

Financial Performance
Metric
ANL
SXC
Price
$10.20
$9.42
Analyst Decision
Strong Buy
Hold
Analyst Count
1
1
Target Price
$20.00
$9.00
AVG Volume (30 Days)
129.2K
1.6M
Earning Date
04-10-2026
04-30-2026
Dividend Yield
N/A
7.17%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,600,300,000.00
Revenue This Year
$36.02
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
10.30
52 Week Low
$0.88
$5.52
52 Week High
$17.25
$9.74

Technical Indicators

Market Signals
Indicator
ANL
SXC
Relative Strength Index (RSI) 40.94 68.42
Support Level $6.92 $7.70
Resistance Level $12.59 $9.74
Average True Range (ATR) 1.15 0.39
MACD -0.11 -0.04
Stochastic Oscillator 26.07 80.19

Price Performance

Historical Comparison
ANL
SXC

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

About SXC SunCoke Energy Inc.

SunCoke Energy Inc operates as an independent producer of coke in the Americas. Its coke is mainly used as a principal raw material in the blast furnace steelmaking process as well as in the foundry production of casted iron. The company operates through two segments: Domestic Coke and Industrial Services. It offers metallurgical and thermal coal. The company also provides handling and/or mixing services to steel, coke, electric utility, coal-producing, and other manufacturing-based customers. The majority of revenue is derived from the Domestic Coke segment.

Share on Social Networks: